SGS has taken over Keystone Bioanalytical in order to further expand its drug development testing services from start to finish for the pharmaceutical and biotechnological industries in North America. By undertaking this purchase, SGS has further strengthened its capabilities in bioanalysis with a particular focus on GLP-compliant services which support the development of both small and large molecule drugs. Established in 2001, Keystone Bioanalytical is a company that mainly develops LC-MS/MS methods, analyzes biomarkers, and profiles drug metabolites. The company provides its services throughout pre-clinical and clinical phases.
Also Read: Servier Strengthens Oncology Portfolio with Day One Biopharmaceuticals Acquisition
“Expanding our GLP-compliant, bioanalysis-focused capabilities within the SGS North American network underscores our commitment to meeting the growing demand for high-quality bioanalytical services,” said Joseph Bower. This step supports the purpose of SGS Strategy 27, which is to speed up the growth of the region in spite of the fact that regulatory authorities such as the FDA and Health Canada are becoming more demanding. With a regional experience of more than thirty years and presence of global network of more than 20 laboratories in 11 countries, SGS is not only cementing its position as an all-round provider of analytical testing services to the life sciences industry.
